Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 4
2008 4
2009 3
2010 13
2011 23
2012 24
2013 25
2014 30
2015 41
2016 43
2017 41
2018 50
2019 32
2020 27
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

315 results
Results by year
Filters applied: . Clear all
Page 1
Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study.
Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O. Kobyliak N, et al. Minerva Med. 2018 Dec;109(6):418-428. doi: 10.23736/S0026-4806.18.05845-7. Epub 2018 Sep 13. Minerva Med. 2018. PMID: 30221912 Clinical Trial.
BACKGROUND: The manipulation of gut microbiota via administration of probiotics has been proposed as a potential strategy for the treatment of non-alcoholic fatty liver disease (NAFLD). Hence, we performed a double-blind single center ran …
BACKGROUND: The manipulation of gut microbiota via administration of probiotics has been proposed as a potential strategy for the treatment …
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E, Byrne CD. Scorletti E, et al. Mol Aspects Med. 2018 Dec;64:135-146. doi: 10.1016/j.mam.2018.03.001. Epub 2018 Mar 22. Mol Aspects Med. 2018. PMID: 29544992 Review.
Since the pathogenesis of non alcoholic fatty liver disease (NAFLD) begins with the accumulation of liver lipid and progresses with inflammation and then several years later with development of fibrosis; it has been thought in pati …
Since the pathogenesis of non alcoholic fatty liver disease (NAFLD) begins with the accumulation o …
Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease.
Shama S, Liu W. Shama S, et al. Dig Dis Sci. 2020 Mar;65(3):906-910. doi: 10.1007/s10620-020-06117-5. Dig Dis Sci. 2020. PMID: 32036510 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease characterized with the spectrum of hepatic steatosis, inflammation, and fibrosis. ...Meanwhile, the omega-3 and omega-6 polyunsaturated …
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease characterized wi …
Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH, Jump DB. Spooner MH, et al. Curr Opin Clin Nutr Metab Care. 2019 Mar;22(2):103-110. doi: 10.1097/MCO.0000000000000539. Curr Opin Clin Nutr Metab Care. 2019. PMID: 30601174 Free PMC article. Review.
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide. ...As such, NAFLD has become a major public health concern. We discuss recent clinical trials and meta-ana …
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver
Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
Yan JH, Guan BJ, Gao HY, Peng XE. Yan JH, et al. Medicine (Baltimore). 2018 Sep;97(37):e12271. doi: 10.1097/MD.0000000000012271. Medicine (Baltimore). 2018. PMID: 30212963 Free PMC article.
BACKGROUND: Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. We performed …
BACKGROUND: Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (omega
Treatment of NAFLD with diet, physical activity and exercise.
Romero-Gómez M, Zelber-Sagi S, Trenell M. Romero-Gómez M, et al. J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016. Epub 2017 May 23. J Hepatol. 2017. PMID: 28545937 Review.
Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. ...Following a Mediterranean diet …
Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients …
Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J, Fernández-Galilea M, Martínez-Fernández L, González-Muniesa P, Pérez-Chávez A, Martínez JA, Moreno-Aliaga MJ. Yang J, et al. Nutrients. 2019 Apr 18;11(4):872. doi: 10.3390/nu11040872. Nutrients. 2019. PMID: 31003450 Free PMC article.
The oxidative-stress theory of aging postulates that age-associated functional losses are due to the accumulation of ROS-induced damage. Liver function impairment and non-alcoholic fatty liver disease (NAFLD) are common among the e …
The oxidative-stress theory of aging postulates that age-associated functional losses are due to the accumulation of ROS-induced damage. …
Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight.
Okada LSDRR, Oliveira CP, Stefano JT, Nogueira MA, Silva IDCGD, Cordeiro FB, Alves VAF, Torrinhas RS, Carrilho FJ, Puri P, Waitzberg DL. Okada LSDRR, et al. Clin Nutr. 2018 Oct;37(5):1474-1484. doi: 10.1016/j.clnu.2017.08.031. Epub 2017 Sep 7. Clin Nutr. 2018. PMID: 29249532 Clinical Trial.
BACKGROUND & AIMS: Currently there is no FDA-approved therapy for nonalcoholic steatohepatitis (NASH). Increased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio can induce endoplasmic reticulum (ER) stress and mitochondrial dysfunction that characterize …
BACKGROUND & AIMS: Currently there is no FDA-approved therapy for nonalcoholic steatohepatitis (NASH). Increased n-6/n-3 polyunsa …
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S. Caldwell S. Clin Mol Hepatol. 2017 Jun;23(2):103-108. doi: 10.3350/cmh.2017.0103. Epub 2017 May 10. Clin Mol Hepatol. 2017. PMID: 28494529 Free PMC article. Review.
Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD). ...Early interest in PUFA derived from their potential benefit in cardio-metabolic disease and the close a
Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver d
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Parker HM, et al. J Hepatol. 2012 Apr;56(4):944-51. doi: 10.1016/j.jhep.2011.08.018. Epub 2011 Oct 21. J Hepatol. 2012. PMID: 22023985 Free article. Review.
Non-alcoholic fatty liver disease (NAFLD) is a frequent accompaniment of obesity and insulin resistance. ...Well designed RCTs which quantify the magnitude of effect of omega-3 PUFA supplementation on liver fat are ne
Non-alcoholic fatty liver disease (NAFLD) is a frequent accompaniment of obesity and insulin resis
315 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page